Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia — Eirini Solia (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia
Shared by
Meletios A Dimopoulos
Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia
Article
2023
en
Authors
ES
Eirini Solia
Meletios A Dimopoulos
EK
Efstathios Kastritis
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2013
Proteasome Inhibitor Therapy for Waldenström's Macroglobulinemia
Meletios A Dimopoulos
,
Evangelos Terpos
,
Efstathios Kastritis
Article
2018
Proteasome Inhibitors in Waldenström Macroglobulinemia
Efstathios Kastritis
,
Meletios A Dimopoulos
Chapter in a book
2016
Immunomodulatory Agents and Proteasome Inhibitors in Waldenstrom’s Macroglobulinemia
Steven P. Treon
,
Jorge J. Castillo
,
Efstathios Kastritis
,
Meletios A Dimopoulos
Article
2005
Diagnosis and Management of Waldenstrom's Macroglobulinemia
Meletios A Dimopoulos
,
Robert A. Kyle
,
Athanasios K. Anagnostopoulos
,
Steven P. Treon
Letter
2008
The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens
Meletios A Dimopoulos
,
Efstathios Kastritis
,
S. Delimpassi
,
Athanasios Zomas
,
Maria‐Christina Kyrtsonis
,
Kostas Zervas
Discussion(0)
No comments yet. Be the first to comment.